Details of the Drug

General Information of Drug (ID: DMVTHWQ)

• Drug Name: Silver sulfadiazine
• Synonyms: Brandiazin; Dermazin; Dermazine; Flamazine; Flammazine; Geben; Sicazine; Silbertone; Silvederma; Silver; Sulfargen; Abbott Brand of Silver Sulfadiazine; Aldo Brand of Silver Sulfadiazine; Major Brand of Silver Sulfadiazine; Medphano Brand of Silver Sulfadiazine; MonarchBrand of Silver Sulfadiazine; Pharmascience Brand of Silver Sulfadiazine; Rhone Poulenc Rorer Brand of Silver Sulfadiazine; SSD AF; SULFADIAZINE SILVER; Sherwood Brand of Silver Sulfadiazine; Silver Sulfafdiazine; Silver sulfadiazinate; Silver sulphadiazine; Solvay Brand of Silver Sulfadiazine; Sulfadiazin silber; Sulfadiazine silver salt; Sulfadiazine silverSilvadene; Zenith Brand of Silver Sulfadiazine; Par Brand 1 of Silver Sulfadiazine; Par Brand 2 of Silver Sulfadiazine; Par Brand 3 of Silver Sulfadiazine; Flamazine (TN); Rhone-Poulenc Rorer Brand of Silver Sulfadiazine; Silvadene (TN); Silver(I) sulfadiazine; Smith & Nephew Brand of Silver Sulfadiazine; Sulfadiazin, silbersalz; Sulfadiazine silver (JP15); Sulfadiazine, Silver [USAN]; Sulfadiazine, silver; Sulfafdiazine, Silver; Thermazene (TN); SSD (1% Silver Sulfadiazine Cream USP); Sulfadiazine, silver (USP); N1-2-Pyrimidinylsulfanilamide monosilver(1+) salt; N(sup 1)-2-Pyrimidinylsulfanilamide monosilver(1+) salt; Silver (4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide; Silver 4-amino-N-pyrimidin-2-ylbenzenesulfonamide; Benzenesulfonamide,4-amino-N-2-pyrimidinyl-, silver complex; Silver(1+) [(4-aminophenyl)sulfonyl](pyrimidin-2-yl)azanide; Sulfanilamide,N1-2-pyrimidinyl-, monosilver(1+) salt; Sulfanilamide, N(sup 1)-2-pyrimidinyl-, monosilver(1+) salt; Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-, monosilver(1+) salt; (4-Amino-N-pyrimidin-2-ylbenzenesulphonamidato-NN,O1)silver; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide silver salt

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Approved	[1], [2], [3]

• Therapeutic Class: Antiinfective Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight; 357.14
  Topological Polar Surface Area; Not Available
  Rotatable Bond Count; 3
  Hydrogen Bond Donor Count; 1
  Hydrogen Bond Acceptor Count; 6
• Chemical Identifiers:
  Formula: C10H9AgN4O2S
  IUPAC Name: silver;(4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide
  Canonical SMILES: C1=CN=C(N=C1)[N-]S(=O)(=O)C2=CC=C(C=C2)N.[Ag+]
  InChI: InChI=1S/C10H9N4O2S.Ag/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10;/h1-7H,11H2;/q-1;+1
  InChIKey: UEJSSZHHYBHCEL-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 441244
  ChEBI ID: CHEBI:9142
  CAS Number: 22199-08-2
  DrugBank ID: DB05245
  TTD ID: D08JCA

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Dihydropteroate synthetase (Bact folP)	TT4ILYC	DHPS_ECOLI	Binder	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4126).
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019608.
• [4] Comparative evaluation of transdermal formulations of norfloxacin with silver sulfadiazine cream, USP, for burn wound healing property. J Burns Wounds. 2006 Jun 7;5:e4.
• [5] In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother. 1995 Apr;39(4):948-52.
• [6] Sulfadiazine/hydroxypropyl-beta-cyclodextrin host-guest system: Characterization, phase-solubility and molecular modeling. Bioorg Med Chem. 2008 May 15;16(10):5788-94.
• [7] Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
• [8] Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7.
• [9] The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
• [10] Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother. 1995 Aug;39(8):1756-63.
• [11] A confirmatory method for the simultaneous extraction, separation, identification and quantification of Tetracycline, Sulphonamide, Trimethoprim an... J Chromatogr A. 2009 Nov 13;1216(46):8110-6.
• [12] Structures of gramicidins A, B, and C incorporated into sodium dodecyl sulfate micelles. Biochemistry. 2001 Oct 2;40(39):11676-86.